Transient antibody expression service

Elevate your research with ProteoGenix’s state-of-the-art recombinant antibody production services where speed meets precision. Receive up to 5 mg of recombinant antibodies in just 10 business days, tailored to your exact specifications. Whether it’s scFv, Fab, VHH, bispecifics, or antibody-fusion proteins, every format and isotype is within reach. With over 30 years of experience and more than 10,000 successful projects driving innovation, and powered by our proprietary XtenCHO system—the industry’s gold standard—expect nothing less than the best. Every antibody is meticulously manufactured in France, embodying the pinnacle of quality and expertise. Ready to transform your research? Choose ProteoGenix, where efficiency, diversity, and unmatched experience come together to redefine recombinant antibody services.

Comprehensive Antibody Format Options

With a comprehensive range of antibody formats and isotypes, our Recombinant Antibody Service empowers you to produce the antibody format of your choice, tailored to your specific research or application needs:

• Antibody Isotypes: Antibody isotypes, or classes, including IgG, IgM, IgA, IgE, and IgD, are characterized by variations in their Fc regions, influencing their distribution and function within the immune system. Each isotype has unique properties suitable for various therapeutic and diagnostic applications. For example, IgG, the most common full-length antibody, is widely used in therapeutic applications due to its ability to facilitate Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC). IgM is the first antibody produced in response to an infection and is effective in initial immune defense. IgA plays a crucial role in mucosal immunity, protecting surfaces such as the gut and respiratory tract. IgE is involved in allergic reactions and defense against parasitic infections, while IgD primarily functions as a receptor on B cells, playing a role in their activation and regulation. This diversity allows for targeted and effective use in various medical and research applications.
• Bispecific Antibodies: Designed to bind two different antigens or epitopes simultaneously, bispecific antibodies are transforming cancer immunotherapy by increasing therapeutic efficacy by targeting two targets simultaneously.
• scFv (Single-chain variable fragment): scFv antibodies are engineered to combine the variable regions of the antibody’s heavy and light chains into a single polypeptide chain. Thehttps://us.proteogenix.science/therapeutic-antibody/bispecific-antibody/se compact molecules retain antigen-binding specificity and are often used in research and diagnostic applications.
• Fab (Fragment antigen-binding): Fab antibodies consist of the variable regions of the heavy and light chains, allowing them to retain antigen-binding capability. They also lack the Fc region, making them useful for certain applications where Fc-mediated effector functions are not required.
• VHH: Also known as nanobodies, VHH are single-domain antibodies derived from heavy-chain-only antibodies found in camelids. They are small and highly stable, making them valuable tools for research, diagnostics, and therapeutics.
• Antibody Fusion-Proteins: These are antibodies fused to other functional proteins or tags. They combine the specificity of an antibody with the functional activity of another protein. They are used in specific applications, such as affinity purification or targeted drug delivery.

The choice of antibody format depends on your specific application. Our team of experts is available to provide guidance and assistance in selecting the optimal recombinant antibody format for your unique project needs.

XtenCHO™: The Gold Standard Expression System for Transient Recombinant Antibody Production

Looking for fast recombinant antibody production services at competitive prices? ProteoGenix’s proprietary XtenCHO™ expression system makes it possible.

Thanks to our in-house Xten transfection protocol, proprietary cell line XtenCHO™, 28+ years of experience in recombinant production, and over 500 successful antibody production projects, we have the market’s most competitive solution.

Thanks to our in-house Xten transfection protocol, proprietary cell line XtenCHO™, 28+ years of experience in recombinant production, and over 500 successful antibody production projects, we have the market’s most competitive solution.

With production yields consistently exceeding even those of ExpiCHO™, we are equipped to overcome your unique antibody expression challenges while keeping production costs low.

Here are some examples of the incredible results obtained in the transient expression of biosimilars

For more detailed results about the use of XtenCHO™ for recombinant antibody production, discover other unbelievable results by downloading our poster or watching Dr. Marcelo Viegas presentation made at the Festival of Biologics (2020).

Case study: Claudiximab Recombinant Antibody Production

Aim Of The Study

Here, we showcase the recombinant antibody production of Claudiximab using our proprietary XtenCHO expression system.

Genes And Expression Vectors

The genes coding for the Heavy chain (HC) and the light chain (LC) of the therapeutic antibody Claudiximab were chemically synthesized with optimization for expression in mammalian cells. The genes were cloned in ProteoGenix’s proprietary mammalian cells expression vector pTXs1. The vector maps is provided in the PDF report.

Small-scale Recombinant Antibody Production And Purification Tests

An endotoxin-free DNA preparation was done for the pTXs1 expression constructions. By using the proprietary Xten transfection protocol, the plasmids were then transiently transfected in the proprietary XtenCHOTM cells.

Culture medium was collected and production yield was determined by Octet Red analysis. The recombinant antibody was then purified by affinity vs. protein G.

Key Benefits of Our Recombinant Antibody Service

Recombinant antibody production is revolutionizing the field of therapeutic and research applications. Unlike traditional methods, this advanced technology allows for precise genetic engineering, leading to antibodies with enhanced specificity and efficacy. With recombinant techniques, you can achieve:

• Ease of engineering and reformatting: Gain precise control over antibody structure at the genetic level. This is critical for the development of therapeutic antibodies as it allows the modulation of pharmacological properties. By modifying the gene expressed by a selected system, we offer a wide range of solutions, including:

1. Reformatting: species, isotype or subtype switching.
2. Antibody engineering: monoclonal antibody humanization, affinity maturation, bispecific antibody, antibody drug conjugates (ADC), antibody fragments (Fab, Fab2, scFv).

• Optimal reproducibility: Ensure a standardized process with minimal batch-to-batch variation with our recombinant antibody production service. As the production process starts from a known antibody or DNA sequence, it also eliminates mutations or cell line drift that can occur in hybridoma cell lines.
• High purity: Achieve high levels of purity in recombinant antibody production thanks to the absence of serum contaminants. The high level of purity ensures that the antibodies perform optimally in your desired applications, providing consistent and reliable results that are critical to scientific success.
• Animal-free production: Produce antibodies without using animals with recombinant antibody technology. Committed to the highest standards of medical ethics and animal welfare, we ensure rapid and efficient antibody production without animal use at any stage.